Who makes Arm T2: Primatene Mist HFA?

Arm T2: Primatene Mist HFA is developed by Amphastar Pharmaceuticals, Inc..

What development phase is Arm T2: Primatene Mist HFA in?

Arm T2: Primatene Mist HFA is in Phase 2.

Last reviewed 2026-05-15 · How we verify

Arm T2: Primatene Mist HFA

Amphastar Pharmaceuticals, Inc. · Phase 2 active Small molecule

At a glance

Generic name	Arm T2: Primatene Mist HFA
Also known as	epinephrine inhalation aerosol
Sponsor	Amphastar Pharmaceuticals, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. (PHASE1, PHASE2)
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Arm T2: Primatene Mist HFA CI brief — competitive landscape report
Arm T2: Primatene Mist HFA updates RSS · CI watch RSS
Amphastar Pharmaceuticals, Inc. portfolio CI